Cardiovascular Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Cardiovascular Disease stocks.

Cardiovascular Disease Stocks Recent News

Date Stock Title
Oct 1 AMRN Amarin Announces Two Upcoming Investor Events
Sep 30 NBIX Neurocrine touts long-term effectiveness of Ingrezza for Huntington's disease chorea
Sep 30 REGN Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sep 30 SMLR Semler Scientific (NASDAQ:SMLR) shareholders have endured a 81% loss from investing in the stock three years ago
Sep 30 NBIX Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
Sep 29 REGN Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Sep 29 REGN Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
Sep 29 REGN Regeneron: Long-Term Defensive Investment
Sep 28 REGN Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Sep 28 REGN Wall Street Breakfast: What Moved Markets
Sep 28 REGN Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
Sep 27 REGN Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Sep 27 REGN Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
Sep 27 REGN FDA greenlights Regeneron’s Dupixent for the treatment of COPD
Sep 27 REGN Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Sep 27 REGN Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
Sep 27 REGN Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Sep 27 REGN Sanofi, Regeneron get additional Chinese approval for Dupixent
Sep 27 REGN Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Sep 27 REGN Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Cardiovascular Disease

Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. Cardiovascular disease includes coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack). Other CVDs include stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.The underlying mechanisms vary depending on the disease. Coronary artery disease, stroke, and peripheral artery disease involve atherosclerosis. This may be caused by high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet, and excessive alcohol consumption, among others. High blood pressure results in 13% of CVD deaths, while tobacco results in 9%, diabetes 6%, lack of exercise 6% and obesity 5%. Rheumatic heart disease may follow untreated strep throat.It is estimated that 90% of CVD is preventable. Prevention of atherosclerosis involves improving risk factors through: healthy eating, exercise, avoidance of tobacco smoke and limiting alcohol intake. Treating risk factors, such as high blood pressure, blood lipids and diabetes is also beneficial. Treating people who have strep throat with antibiotics can decrease the risk of rheumatic heart disease. The use of aspirin in people, who are otherwise healthy, is of unclear benefit.Cardiovascular diseases are the leading cause of death globally. This is true in all areas of the world except Africa. Together they resulted in 17.9 million deaths (32.1%) in 2015, up from 12.3 million (25.8%) in 1990. Deaths, at a given age, from CVD are more common and have been increasing in much of the developing world, while rates have declined in most of the developed world since the 1970s. Coronary artery disease and stroke account for 80% of CVD deaths in males and 75% of CVD deaths in females. Most cardiovascular disease affects older adults. In the United States 11% of people between 20 and 40 have CVD, while 37% between 40 and 60, 71% of people between 60 and 80, and 85% of people over 80 have CVD. The average age of death from coronary artery disease in the developed world is around 80 while it is around 68 in the developing world. Disease onset is typically seven to ten years earlier in men as compared to women.

Browse All Tags